Medifast Q3 revenue falls 19.4% to $72.0 million; net loss widens to $17.5 million
Medifast reported third quarter 2026 revenue of $72.0 million, down 19.4% from $89.4 million a year earlier, as active earning coaches fell 47.7% to 10,200. The company posted a net loss of $17.5 million, or $1.57 per share, compared with a loss of $2.3 million, or $0.21 per share, a year earlier, and it expects coach numbers to keep declining through the end of 2026. For shareholders, the filing shows weaker sales and a larger loss, partly driven by Catalyst Restructuring charges, with full-year 2026 loss per share guidance of $1.80 to $2.05.
Key points
- Revenue $72.0 million, down 19.4% from $89.4 million; active earning coaches 10,200, down 47.7% from 19,500
- Net loss $17.5 million, or $1.57 per diluted share; non-GAAP adjusted net loss $2.1 million, or $0.19 per share
- Fourth quarter 2026 revenue guided to $55 million to $75 million; full-year 2026 revenue guided to $280 million to $300 million
- Cash, cash equivalents and investment securities of $172.5 million with no debt as of September 30, 2026
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.